EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterizing the in vitro and in vivo effect of bicarbonate on azithromycin activity against Acinetobacter baumannii

Hadley Jaramillo, Matthew Slarve, Derek Long iD, Michelle Zorawik, Kristine Goy, Lauren Popel, Rosemary She, Brad Spellberg, Brian Luna iD

PLOS One · 03.06.2026 · 21 (6) · e0350230

DOI: 10.1371/journal.pone.0350230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 03.06.2026. Verfasst von Hadley Jaramillo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Immune Therapeutics, Keck School of Medicine at USC, Los Angeles, California, United States of America. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Bicarbonates, Azithromycin, Anti-Bacterial Agents. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, FDA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenem-resistant Acinetobacter baumannii (CRAB), a Gram-negative bacterial pathogen, has been identified by Centers for Disease Control (CDC) as the top priority pathogen for which new antibiotics are needed. We found that the addition of bicarbonate at physiologically normal levels found in the blood (23.8 mM) increased susceptibility of A. baumannii clinical isolates (n = 63) to azithromycin and resulted in MIC50 shift from 64 mg/L in CAMHB to 1–2 mg/L in CAMHB + bicarbonate (23.8 mM) or RPMI-1640 respectively. To characterize in vivo efficacy in murine blood and lung infection models, mice were infected with A. baumannii and then mice were treated with a human equivalent dosing strategy of azithromycin. In vivo outcomes greatly depended on the infection model used. The bloodstream infection model showed a statistically significant increase in survival of the treatment group compared to the control group. However, that was not found with the oral aspiration infection model. We hypothesize that these in vivo results are due to the local differences of bicarbonate concentrations at the site of infection throughout the course of infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiBicarbonatesAzithromycinAnti-Bacterial AgentsAcinetobacter InfectionsAnimalsMiceMicrobial Sensitivity TestsHumansFemaleDisease Models, Animal

Substanzen

BicarbonatesAzithromycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Immunology and Immune Therapeutics, Keck School of Medicine at USC, Los Angeles, California, United States of America.
  • Department of Pathology, City of Hope, Duarte, California, United States of America.
  • Los Angeles General Medical Center, Los Angeles, California, United States of America.

ORCID-Profile: Derek Long, Brian Luna

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • FDA

Zitieren

APA

Jaramillo, H., Slarve, M., Long, D., Zorawik, M., Goy, K., Popel, L., She, R., Spellberg, B., & Luna, B. (2026). Characterizing the in vitro and in vivo effect of bicarbonate on azithromycin activity against Acinetobacter baumannii. PLOS One, 21(6), e0350230. https://doi.org/10.1371/journal.pone.0350230

Vancouver

Jaramillo H, Slarve M, Long D, Zorawik M, Goy K, Popel L, et al. Characterizing the in vitro and in vivo effect of bicarbonate on azithromycin activity against Acinetobacter baumannii. PLOS One. 2026;21(6):e0350230. doi:10.1371/journal.pone.0350230

BibTeX
@article{Jaramillo2026,
  author = {Jaramillo, Hadley and Slarve, Matthew and Long, Derek and Zorawik, Michelle and Goy, Kristine and Popel, Lauren and She, Rosemary and Spellberg, Brad and Luna, Brian},
  title = {Characterizing the in vitro and in vivo effect of bicarbonate on azithromycin activity against Acinetobacter baumannii},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {6},
  pages = {e0350230},
  doi = {10.1371/journal.pone.0350230}
}
Kostenlos starten →